News

Edoxaban, being developed solely by Daiichi Sankyo, is an oral anticoagulant that directly and specifically inhibits Factor Xa. Reportedly, the results from pivotal Phase III studies showed that

CytRx expects to enroll up to 50 patients with metastatic hormone-refractory prostate cancer who have failed first-line therapy with either the chemotherapy agent docetaxel or mitoxantrone in this

The data analysis has confirmed that the trial has met its end points of demonstrating safety and tolerability. In addition, the treatment has shown proof of principle of

The agreement provides CancerGuide with exclusive commercial rights to a portfolio of well-published and rigorously-validated molecular signatures that predict response for targeted therapeutics as well as collaborative access

Pitavastatin is a new statin for the treatment of hypercholesterolemia. As per the agreement, Esteve is expected to co-market the product together with Recordati Espana, the Spanish subsidiary

According to JR Vyas, managing director of the company, the planned finances would help fund the manufacturing facilities. The four new proposed plants, scheduled to open 15 months

As per the collaboration, the parties will explore the use of both existing and proprietary delivery approaches for dermatological applications. Each party will contribute technology and resources to

Machaon’s FDA-approved array-based technology detects genetic variations in 2 key genes involved in the metabolism of warfarin. 40% of the general population in the US are said to

Cantox and Ashuren are global scientific research and regulatory consulting organisations providing solutions for clients in food and nutrition, agriculture, biotechnology, consumer products, chemicals, pharmaceuticals and healthcare. The